¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"germ line gene therapy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • growth arrest line
    ¼ºÀåÁ¤Áö¼±
  • growth line
    ¼ºÀå¼±
  • growth recovery line
    ¼ºÀåȸº¹¼±
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
  • intravenous line
    Á¤¸ÆÁֻ缱
  • isoelectric line
    µîÀü¼±
  • isothermal line
    µî¿Â¼±
  • inbred line
    ¼ø°è
  • incremental line
    Áõ½Ä¼±, ¼ºÀå¼±
  • lead line
    ³³¼±
  • life line
    1. »ý¸íÀüÈ­ 2. »ý¸í±¸Á¶¼±
  • line
    1. ¼± 2. °è
  • M line
    Áß°£°¡·Î¸·
  • major dense line
    ūġ¹Ð¼±
  • midaxillary line
    Áß°£°Üµå¶û¼±, ¾×¿ÍÁß°£¼±
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • fixation line
    Áֽü±
  • gingival line
    ÀÕ¸ö¼±
  • gluteal line
    º¼±â±Ù¼±
  • gravitational skin line
    Áß·ÂÇǺμ±
  • growth line
    ¼ºÀå¼±
  • growth arrest line
    ¼ºÀåÁ¤Áö¼±
  • growth recovery line
    ¼ºÀåȸº¹¼±
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
  • inbred line
    ¼ø°è
  • incremental line
    Áõ½Ä¼±
  • isoelectric line
    (¢¡base line) ¹ÙÅÁ¼±, ±âÁؼ±
  • isothermal line
    µî¿Â¼±
  • line
    ¼±, °è
  • lead line
    ³³¼±
  • life line
    »ý¸íÀüÈ­, »ý¸í±¸Á¶¼±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • androgen therapy
    ³²¼ºÈ£¸£¸ó ¿ä¹ý
  • antiandrogenic therapy
    Ç׳²¼ºÈ£¸£¸ó¿ä¹ý.
  • anticoagulant therapy
    Ç×ÀÀ°í¿ä¹ý.
  • antiestrogen therapy, for sexual dysfunction
    Ç׿¡½ºÆ®·Î°Õ ¿ä¹ý(¼º±â´ÉÀå¾ÖÀÇ)
  • antifungal therapy
    Ç×°õÆÎÀÌÄ¡·á
  • antimicrobial therapy
    Ç×±Õ¿ä¹ý(ù÷жèþÛö).
  • art therapy
    ¿¹¼ú¿ä¹ý
  • fractionated stereotactic radiation therapy
    ºÐÇÒÁ¤À§ ¹æ»ç¼±Ä¡·á
  • gold therapy
    ±Ý Ä¡·á
  • gonadotropin therapy
    ¼º¼±ÀÚ±ØÈ£¸£¸ó¿ä¹ý.
  • grenz-ray therapy
    ±×·£Â꼱ġ·á
  • health resort therapy
    ÀüÁö¿ä¹ý(ÊÙËíËÑ).
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý<--Ä¡·á>°¨½Ã
  • hyperbaric oxygen therapy
    °í¾Ð»ê¼Ò¿ä¹ý
  • hyperbaric oxygenation therapy
    °í¾Ð»ê¼Ò¿ä¹ý(ÍÔäâß«áÈèþÛö)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • gene frequency
    À¯ÀüÀÚºóµµ.
  • gene frequency
    À¯ÀüÀÚºóµµ
  • gene genetics
    À¯ÀüÀÚÀ¯ÀüÇÐ(¡­ë¶îîùÊ).
  • gene imbalance
    À¯ÀüÀÚºÒÆòÇü(ÝÕøÁû¬).
  • gene imbalance
    À¯ÀüÀÚºÒÆòÇü.
  • gene map
    À¯ÀüÀÚÁöµµ
  • gene map order
    À¯ÀüÀÚÁöµµ¼ø¼­
  • gene mutation
    ÇØºÎ
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ(ÔÍæÔܨì¶).
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ.
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ.
  • gene mutation
    À¯ÀüÀÚ(µ¹¿¬)º¯ÀÌ
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ(î¢ðÚùê).
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ.
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • mit gene
    mit À¯ÀüÀÚ(ë¶îîí­)
  • MIT gene
    MIT À¯ÀüÀÚ(ë¶îîí­)
  • modification gene
    ¼ö½ÄÈ¿¼Ò À¯ÀüÀÚ(áóãÞý£áÈë¶îîí­)
  • modifying gene
    ¼ö½ÄÀ¯ÀüÀÚ(áóãÞë¶îîí­)
  • morphogenetic gene
    ÇüÅÂÇü¼ºÀ¯ÀüÀÚ(û¡÷¾û¡à÷ë¶îîí­)
  • morphopoietic gene
    ÇüÅÂÀ¯ÀüÀÚ(û¡÷¾ë¶îîí­)
  • multiple gene
    ´ÙÀ¯ÀüÀÚ(Òýë¶îîí­)
  • mutable gene
    °¡º¯ÀÌÀ¯ÀüÀÚ(ʦܨì¶ë¶îîí­)
  • mutant gene
    º¯ÀÌÀ¯ÀüÀÚ(ܨì¶ë¶îîí­)
  • mutator gene
    º¯ÀÌÀÚ À¯ÀüÀÚ(ܨì¶í­ë¶îîí­)
  • negative gene control
    À½À¯ÀüÀÚÁ¦¾î(ëäë¶îîí­ð¤åÙ)
  • nif gene
    nif À¯ÀüÀÚ(ë¶îîí­)
  • nonessential gene
    ºñÇʼöÀ¯ÀüÀÚ(Þªù±áóë¶îîí­)
  • one-gene-one-enzyme hypothesis
    ÀÏÀ¯ÀüÀÚÀÏÈ¿¼Ò¼³(ìéë¶îîí­ìéý£áÈàã)
  • one-gene-one-polypeptide chain hypothesis
    ÀÏÀ¯ÀüÀÚ(ìéë¶îîí­) ÀÏ(ìé)Æú¸®ÆéŸÀÌµå »ç½½¼³(àã)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
GnRH Gonadotropin Releasing Hormone  [HP 1898, 2034]
  = LHRH
  = Go...
ARGS antitrypsin-related gene sequence
CAP camptodactyly-arthropathy-pericarditis [syndrome]; Canada Assistance Plan; capsule; captopril; catab...
CGA catabolite gene activator; color graphics adapter
CGP N-carbobenzoxy-glycyl-L-phenylalanine; chorionic growth hormone-prolactin; choline glycerophosphatid...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
FSL Flinder sensitive line
FRL Flinders Resistant Line
FLN Fluorescence Line Narrowing
GDNF GLIAL cell-line derived neurotrophic factor
L1 LINE-1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • aversion therapy
    Çø±â¿ä¹ý
    ¿øÇÏÁö ¾Ê´Â Çൿ ÆÐÅÏÀ» ºÒÄèÇÑ Àڱذú °áºÎ½ÃŰ´Â °Í. ¶Ç´Â ¿øÇÏÁö ¾Ê´Â ÇàÀ§·ÎºÎÅÍ ºÒÄèÇÑ ÀÚ±ØÀÌ »ý±âµµ·Ï ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÑ Ä¡·á.
  • behavior therapy
    Çൿ ¿ä¹ý, Çൿ Ä¡·á
    Á¤½Å°úÀû Ä¡·á ¹æ¹ýÀÇ Çϳª. ¹«ÀǽÄÀûÀÎ ¿ä¼Ò³ª ³»ºÎ °¥µî µîÀÇ ´«¿¡ º¸ÀÌÁö ¾Ê´Â °ÍÀ» ´ë»óÀ¸·Î ÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó Á÷Á¢ °üÂûÇÒ ¼ö ÀÖ´Â ÇൿÀ» ´ë»óÀ¸·Î Ä¡·áÇÑ´Ù. ƯÁ¤ ȯ°æÀ» ¼³Á¤Çϰí À̰Ϳ¡ ´ëÇØ¼­ ¹Ù¶÷Á÷ÇÑ ÇൿÀ» ÇÏ°Ô ¸¸µé¾î º¯È­½ÃŰ°í ½ÍÀº ÇൿÀ» °íÃijª°¡´Â ¹æ¹ýÀÌ´Ù. ÇнÀ ÀÌ·ÐÀ» ½Å°æÁõÀû ÇൿÀ̳ª ºÎÀûÀÀ Çൿ µîÀÇ ÀÌ»ó Çൿ¿¡ Àû¿ëÇϰí Çൿ º¯¿ëÀ» ²ÒÇÏ·Á´Â ÀÓ»ó½É¸®ÇÐÀû Ä¡·á¹ýÀÇ ÃÑĪ.
  • biofeedback therapy
    ¹ÙÀÌ¿ÀÇǵå¹é ¿ä¹ý
  • biologic therapy
    »ý¹°ÇÐÀû Á¦Á¦ ¿ä¹ý
  • biostimulation therapy
    »ýü ÀÚ±Ø Ä¡·á, »ýü ÀÚ±Ø ¿ä¹ý
  • cognitive therapy
    ÀÎÁö Ä¡·á, ÀÎÁö ¿ä¹ý
  • cold laser therapy
    ³Ã ·¹ÀÌÀú ¿ä¹ý
    infrared laser thera
  • conformal dynamic therapy
    ÀÔü Á¶Çü µ¿Àû Ä¡·á
  • convulsive shock therapy
    °æ·Ã ¼ï ¿ä¹ý
  • corrective therapy
    ±³Á¤ ¿ä¹ý
  • cryoprobe therapy
    ³Ãµ¿ Žħ¼ú
  • definitive occlusal therapy
    ÃÖÀûÀÇ ±³ÇÕ Ä¡·á
  • distal point therapy
    ¿øµµ ÃëÇ÷ ¿ä¹ý
  • drug therapy
    ¾à¹° º¹¿ë
  • dual-sex therapy
    ÀÌÁß ¼º ¿ä¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
postremission therapy Chemotherapy to kill leukaemia cells that survive after remission induction therapy.
(12 Dec 1998)
cytoreductive therapy Therapy with the intention of reducing the number of cells in a lesion, usually a malignancy.
(05 Mar 2000)
salvage therapy <oncology> The final possible treatment for people who are nonresponsive to or cannot tolerate other available treatments for a particular condition.
(14 Oct 1997)
proliferation therapy Rehabilitation of an incompetent structure (ligament or tendon) by the induced proliferation of new cells; accomplished by injecting an irritating substance into the loose ligament or tendon, the resulting scar formation and contracture serving to tighten up the ligament or tendon as scar tissue proliferates.
(05 Mar 2000)
protein shock therapy The injection of a foreign protein to induce fever as a means of treating certain diseases.
Synonym: foreign protein therapy.
(05 Mar 2000)
heterovaccine therapy Therapy with a vaccine obtained from organisms not directly concerned with the disorder being treated.
(05 Mar 2000)
sclerosing therapy A procedure which involves the injection of a sclerosing agent (causes scarring) into varicose veins in the extremities. Sclerotherapy may also be performed in the oesophagus, using UGI endoscopy, in the treatment of oesophageal varices in patients with cirrhosis of the liver.
(27 Sep 1997)
X-ray therapy Radiation therapy using X-rays; sometimes used ironically to refer to excessive use of diagnostic radiation.
(05 Mar 2000)
psychedelic therapy Psychiatric therapy utilizing psychedelic drugs.
(05 Mar 2000)
psychoanalytic therapy A form of psychiatric treatment, based on freudian principles, which seeks to eliminate or diminish the undesirable effects of unconscious conflicts by making the patient aware of their existence, origin, and inappropriate expression in current emotions and behaviour.
(12 Dec 1998)
home infusion therapy Use of any infusion therapy on an ambulatory, outpatient, or other non-institutionalised basis.
(12 Dec 1998)
home oxygen therapy A form of oxygen that is typically delivered via nasal cannula. Commonly provided to those with severe heart or lung disease.
See: chronic obstructive pulmonary disease.
(27 Sep 1997)
pulse therapy A short, intensive course of pharmacotherapy, usually given at intervals such as weekly or monthly; often used in chemotherapy of malignancy.
(05 Mar 2000)
hormonal therapy Treatment of cancer by alteration of the hormonal balance. Some cancer will only grow in the presence of certain hormones.
(09 Oct 1997)
hormone replacement therapy In females, treatment with sex hormones for a number for reasons, including menopause, partial or full hysterectomy, or amenorrhoea.In women, treatment with sex hormones is indicated for a number of reasons, including menopause, partial or full hysterectomy, or amenorrhoea. After menopause, conjugated oestrogens, estradiol, or estrone sulfate are given to reduce pain during intercourse, limit blood vessel effects, and prevent loss of bone mass. After radical hysterectomy, conjugated oestrogens are given for similar reasons. After menopause or partial hysterectomy, progestin is administered at the same time to offset an increased risk of endometrial cancer. In some amenorrhoeas, oestrogen is given to restore menses; if the therapy is unsuccessful, this may indicate the presence of pathology, for instance, pituitary tumour. Benefits for postmenopausal women include a lowered risk of heart attack (oestrogen lowers LDL and raises HDL levels), and prevention of osteoporosis, since the rate of bone loss is directly linked to a drop in oestrogen levels (see perimenopause). Medical opinion about the hazard posed by such therapy remains divided. Some studies have indicated increased incidence of breast cancer; however, a comprehensive 1992 review of the literature contradicted this finding.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • fathom line
    Ãø¿¬¼±
  • fault line
    ´ÜÃþ¼±
  • feeder line
    Áö¼±
  • field line
    ÈûÀÇ ¼±
  • finish line
    °á½Â¼±
  • fire line
    ¹æÈ­¼±;¼Ò¹æ ½Ã»ó¼±
  • firing line
    »ç¼±;Æ÷¿­¼±;»ç¼±ºÎ´ë;Á¦Àϼ±;ÃÖ¼±ºÀ
  • fishing line
    ³¬½ËÁÙ
  • flight line
    (°Ý³³°í ÁÖº¯ÀÇ) ºñÇà ´ë±â¼±;(ºñÇà±â,ö»õÀÇ) ºñÇà °æ·Î
  • flow line
    À¯¹®(È­¼º¾Ï À¯µ¿ ¶§¿¡ »ý±â´Â ÁÙ¹«´Ì)
  • forbidden line
    (½ºÆåÆ®·³ÀÇ) ±ÝÁ¦¼±
  • foul line
    ÆÄ¿ï¼±
  • frame line
    Å׵θ® ¼±;(¿µÈ­ Çʸ§ÀÇ) Å丷ÁÙ
  • front line
    (Ȱµ¿,ÅõÀï¿¡¼­ Ã¥ÀÓÀÖ´Â ÀÔÀå¿¡ ¼­´Â)¼±µÎ;ÃÖÀü¼±;Àü¼±
  • frost line
    ÁöÇÏ µ¿°á ÇѰ輱
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á